ArticleFrontiers in pharmacology2026
Safety profile of azvudine in COVID-19 patients with renal impairment: a retrospective analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Azvudine (FNC), an antiviral drug approved in China for the treatment of Coronavirus disease 2019 (COVID-19) infection, has not yet established a well-defined safety profile in patients with renal impairment. This study aimed to evaluate the safety of using FNC in patients with renal impairment. Methods: We conducted a retrospective analysis of clinical data from 328 COVID-19 patients to assess FNC-related adverse drug events (ADEs). Patients were stratified into two cohorts: a control group with an estimated glomerular filtration rate (eGFR) > 70 mL/min/1.73 m Results: Over half of the cohort (51.8%) experienced FNC-associated ADEs, predominantly hepatic function abnormalities (36.6%) and renal function abnormalities (18.9%). The incidence of acute kidney injury (AKI) was 8.8%. Patients with renal impairment exhibited a higher risk of ADEs, particularly among elderly individuals and patients with a high neutrophil count. No differences in hepatic function abnormalities were found between the two groups. Patients with renal impairment had a higher risk of renal function abnormalities and AKI, with decreased eGFR identified as an independent risk factor for these ADEs. The predictors included in the nomogram model for AKI were neutrophil count and eGFR grade. The nomogram model demonstrated predictive performance and calibration, with an area under the curve of 0.812. Conclusion: These findings highlight the need for enhanced safety monitoring and potential dose adjustments when administering FNC to COVID-19 patients with renal impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.